Onychomycosis Research

GX-03 for the Treatment of Onychomycosis

Market opportunity driven by large population of patients that go untreated, as well as limited safe and effective options.

Onychomycosis is a highly prevalent fungal infection affecting ~35M people in the US.

Key Facts:

  • Fungal infection of the nail and nail bed.
  • Without treatment, it can damage the nail unit and spread to other toes and skin.
  • Affects 1 in 10 people, 85% of whom do not seek treatment due to limited safe and effective options.
  • Affects 1 in 3 diabetics, increasing risk of secondary infections, foot disorders and limb amputations.
  • Local, non life-threatening infection – fundamentally should be treated topically.

The company learned through the discovery of investigator initiated research that GX-03 shows impressive effectiveness against onychomycosis, including chronic onychomycosis.

To cure onychomycosis, the optimal topical drug must be small, occlusive, and lipid based in order to penetrate lipid bilayers in the nail and reach the nail bed. Fungus resides in the nail bed; if the drug cannot reach the nail bed, it cannot cure the disease.

Our technology penetrates the keratin, carries active ingredients through the channels of the lipid bilayers, and delivers powerful medicinals directly to the site of infection.


Our work—aimed at discovering cures—is a constant evolution and a challenge to the status quo. If modern medicine is the book, we will be the next breakthrough chapter.

– Bradley Burnam, CEO

Turn Therapeutics Reaches Licensing and Distribution Agreement with MIMEDX